AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

The ESR1-CCDC170 Gene Fusion as a Diagnostic Biomarker for Breast Cancer

Technology Benefits

- Novel diagnostic/prognostic marker: genetically define a subset of luminal B breast cancers by using widely adopted nucleic acid analysis technologies to detect the said gene fusion.- A "yes or no" genetic marker: the ESR1-CCDC170 gene fusion detection test will yield a clear "yes or no" result, eliminating the need of any empirical threshold or cut-off scores.- Personalized medicine: Detection of the ESR1-CCDC170 gene fusion can be used as an independent or companion diagnostic to screen for patients who are likely to develop endocrine resistance and require enhanced treatment strategy such as chemotherapy.

Detailed Technology Description

Publications:Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJ, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS. Nat Commun. 2014 Aug 7;5:4577. (http://www.ncbi.nlm.nih.gov/pubmed/25099679)

Country/Region

USA

For more information, please click Here